Is 4D Molecular Therapeutics, Inc. (FDMT) a Buy, Sell, or Hold?
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$11.7 USD
$0.4 (3.54%)
- Volume
- 651.78K
- Average Volume
- 872.77K
- Market Capitalization
- $611.63M
- P/E Ratio
- -4.40
- Dividend Yield
- 0.00%
- Price Target
- $33.00
- Year High
- $14.00
- Year Low
- $4.11
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.34
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | David H. Kirn |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | FDMT |
| CUSIP | 35104E100 |
| CIK | 0001650648 |
| Web | https://www.4dmoleculartherapeutics.com |
| Phone | 510 505 2680 |
| Currency | USD |
| Employees | 196 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.05 |
| Payout Ratio | 0.00 |
| Current Ratio | 9.34 |
| Quick Ratio | 9.34 |
| Cash Ratio | 1.67 |
Sales & Book Value
| Annual Sales | $85.21M |
| Price / Sales | 6.93 |
| Cash Flow | -1.91 |
| Price / Cash Flow | -4.70 |
| Price / Book | 1.76 |
Price Target and Rating
| Average Stock Price Forecast | $33.00 |
| High Stock Price Forecast | $33.00 |
| Low Stock Price Forecast | $33.00 |
| Forecast Upside/Downside | -64.55% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.42 |
| Trailing P/E Ratio | -4.40 |
| PEG Ratio | -1.00 |
| P/E Growth | -1.00 |
| Net Income | $-140.11M |
| Net Margin | -182.34% |
| Pretax Margin | -182.34% |
| Return on Equity | -36.83% |
| Return on Assets | -31.37% |
Financials Score
| AltmanZ Score | 3.59 |
| Piotroski Score | 3.00 |
| Working Capital | 361.96M |
| Total Assets | 512.9M |
| Ebit | -169.89M |
| Market Cap | 590.72M |
| Total Liabilities | 61.07M |
Poll Results
About 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating w ... et age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
2026-06-30 16:05:00
EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Montreal, Canada, from July 15 - 18, 2026.
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
2026-06-29 08:00:00
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to $200 million.
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
2026-06-29 08:00:00
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced enrollment completion for 4FRONT-2, the second Phase 3 clinical trial in our global program, evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?
2026-06-23 10:45:53
4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
4DMT Announces New Employment Inducement Grants
2026-06-12 16:05:00
EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on June 9, 2026, the compensation committee of the Company's board of directors granted seven new non-executive employees 66,900 Restricted Stock Units (RSUs).
2026-06-10 00:22:09
4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-06-05 17:52:55
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
4DMT to Participate in Upcoming Investor Conferences
2026-05-27 08:00:00
EMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in June.
Frequently Asked Questions
-
What is the current 4D Molecular Therapeutics, Inc. (FDMT) stock price?
-
4D Molecular Therapeutics, Inc.(NASDAQ:FDMT) stock price is $11.7 in the last trading session. During the trading session, FDMT stock reached the peak price of $14 while $4.11 was the lowest point it dropped to. The percentage change in FDMT stock occurred in the recent session was 3.54% while the dollar amount for the price change in FDMT stock was $0.4.
-
FDMT's industry and sector of operation?
-
The NASDAQ listed FDMT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of FDMT?
-
Alan H. Cohen FAAAAI FAAP FACAAI FCCP | Senior Vice President & Therapeutic Area Head of Pulmonology
Noriyuki Kasahara | Chief Scientific Advisor
John F. Milligan | Executive Chairman
Theresa Janke | Co-Founder & Chief of Staff
An Song | Chief Translational Medicine Advisor -
How many employees does FDMT have?
-
Number of FDMT employees currently stands at 196. FDMT operates from 5858 Horton Street, EmeryVille, CA 94608, US.
-
Link for FDMT official website?
-
Official Website of FDMT is: https://www.4dmoleculartherapeutics.com
-
How do I contact FDMT?
-
FDMT could be contacted at phone #510 505 2680 and can also be accessed through its website. FDMT operates from 5858 Horton Street, EmeryVille, CA 94608, US.
-
How many shares of FDMT are traded daily?
-
The average number of FDMT shares traded daily for last 3 months was 872.77K.
-
What is the market cap of FDMT currently?
-
The market value of FDMT currently stands at $611.63M with its latest stock price at $11.7